Home>Topics>Stocks>InterMune

InterMune ITMN

  1. All
  2. Commentary
  3. Headlines
    1. Roche Reports 3Q Sales In Line With Our Expectations; Maintain Fair Value Following Esbriet Approval

      Commentary

      Thu, 16 Oct 2014

      increased expectations for pricing ($80,000 in the U.S.) and market penetration (25% peak). The acquisition of InterMune closed at the end of September, and Esbriet received approval on Oct. 15 in the U.S. Diagnostics growth stands at 6

    2. Roche's Acquisition of InterMune Comes at Steep Price, but We're Maintaining Our Roche FVE

      Commentary

      Mon, 25 Aug 2014

      has announced that it plans to acquire InterMune for $74 per share, or $8.3 billion ..... which represents a 63% premium to InterMune 's $45 share price prior to the start ..... close this year, and we're raising our InterMune fair value estimate to match the offer

    3. InterMune Reports Solid 2Q Esbriet Sales; Takeover Expectations Appear Baked Into Price

      Commentary

      Thu, 7 Aug 2014

      InterMune reported second-quarter results that were consistent with our expectations ..... materially affect our valuation. The current regulatory timeline for InterMune is a six-month Food and Drug Administration review, based on the drug

    4. InterMune to resubmit lead drug for US approval after trial success

      Headlines

      Mon, 19 May 2014

      May 19 (Reuters) - InterMune Inc shares jumped as much as 15 percent on Monday, after the biotechnology company said it would resubmit for U.S. approval its drug to treat a fatal lung disease after...

    5. Detailed Phase III Results Give Esbriet the Edge Over Competition; Increasing Our FVE to $32

      Commentary

      Mon, 19 May 2014

      results of Phase III clinical trials for InterMune ’s Esbriet and Boehringer Ingelheim ..... our no-moat, stable trend rating for InterMune . The general view from physicians was ..... The current regulatory timeline for InterMune is to resubmit its application to the

    6. InterMune Reports Strong 1Q Esbriet Sales; Maintaining Fair Value Estimate

      Commentary

      Fri, 2 May 2014

      InterMune reported first-quarter results that were better than our expectations and increased its Esbriet guidance for the year. Nevertheless

    7. InterMune shares jump as Boehringer's rival drug shows mixed results

      Headlines

      Fri, 21 Mar 2014

      BANGALORE (Reuters) - Shares of InterMune Inc rose as much as 17 percent on Friday after data showed German drugmaker Boehringer Ingleheim's rival drug had mixed results in late-stage trials.

    8. Positive Phase III Data from Boehringer Ingelheim, but No Clear Winner in IPF Market

      Commentary

      Fri, 21 Mar 2014

      limited detail to directly compare with InterMune ’s Phase III results, the key takeaway ..... Overall, this does not change our view on InterMune ’s prospects as we were anticipating ..... our market model for Esbriet. While InterMune ’s stock is reacting positively to the

    9. InterMune's 2014 Guidance Is Positive, but Key Value Driver Remains Q2 Esbriet Trial Results

      Commentary

      Thu, 9 Jan 2014

      InterMune announced preliminary fourth-quarter ..... Overall, this is positive news for InterMune , and we are maintaining our $17 per share ..... potentially lucrative market. For 2013, InterMune ’s revenue was $70.2 million

    10. Maintaining Our InterMune Fair Value Estimate as Esbriet Sales Continue to Ramp Up in Europe

      Commentary

      Wed, 24 Jul 2013

      per share fair value estimate for InterMune ITMN following the release of second ..... limited drug lineup has prevented InterMune from establishing an economic moat ..... S.--as the key driver for InterMune shares, and top-line results

    « Prev1234Next »
    Content Partners